Goldman Sachs Group Inc Eye Point Pharmaceuticals, Inc. Put Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding EYPT
# of Institutions
150Shares Held
58MCall Options Held
177KPut Options Held
263K-
Cormorant Asset Management, LP Boston, MA8.33MShares$59.1 Million4.66% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$36.7 Million1.63% of portfolio
-
Franklin Resources Inc San Mateo, CA4.01MShares$28.5 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.79MShares$26.9 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$26.7 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $242M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...